Why tocilizumab could be an effective treatment for severe COVID-19?
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.
['Fu|Binqing|B|', 'Xu|Xiaoling|X|', 'Wei|Haiming|H|0000-0002-1675-6502']
D061067:Antibodies, Monoclonal, Humanized D000073640:Betacoronavirus D000086382:COVID-19 D018352:Coronavirus Infections D006801:Humans D015850:Interleukin-6 D058873:Pandemics D011024:Pneumonia, Viral D000086402:SARS-CoV-2 D012720:Severity of Illness Index
Tocilizumab COVID-19 Acute respiratory distress syndrome (ARDS) Inflammatory storm IL-6 SARS-CoV-2